Bill Gates reportedly warned Trump his foundation won't be able to fund global health gaps if the administration keeps making major cuts
Bill Gates has reportedly warned President Donald Trump's administration that his philanthropic endeavors are no replacement for the U.S. government's funding of global health care efforts.
The Microsoft cofounder turned billionaire philanthropist is petitioning the Trump administration to continue funding worldwide health programs Reuters reported, citing two anonymous sources. Gates has met with legislators and the National Security Council about his concerns.
The Trump administration effectively dissolved the U.S. Agency for International Development, the body responsible for mass public health campaigns, including carrying out mass measles vaccination efforts. Last month, the administration dissolved 90% of the agency's foreign aid contracts and put the majority of its workers on leave, firing 1,600 others. USAID distributed $43.8 billion in aid in fiscal 2023, according to Pew Research.
'President Trump will support polices [sic] that bolster our public health, cut programs that do not align with the agenda that the American people gave him a mandate in November to implement, and keep programs that put America First,' White House deputy press secretary Anna Kelly told Fortune in a statement.
Public health experts fear the White House's USAID scrapping could have devastating global consequences, such as a rise in global malaria cases and deaths and the spread of HIV and tuberculosis (TB).
'Without immediate action, hard-won progress in the fight against TB is at risk,' Dr. Tereza Kasaeva, director of the WHO's Global Programme on TB and Lung Health, said in a statement earlier this month.
The Gates Foundation, founded by Bill Gates and ex-wife Melinda French Gates in 2000, has a nearly $9 billion budget for 2025 and has funded malaria vaccine testing and the Gavi Alliance's childhood immunization efforts.
The foundation did not respond to Fortune's request for comment but told Reuters in a statement, 'Bill was recently in Washington, D.C., meeting with decision makers to discuss the lifesaving impact of U.S. international assistance and the need for a strategic plan to protect the world's most vulnerable while safeguarding America's health and security.'
Trump's mission to curb global foreign aid would increase pressure on private organizations to pick up the slack, something philanthropic groups seem unwilling to do. Gates met with Trump at the White House in early February, calling on the administration to continue funding USAID. The Gates Foundation has made it clear that no private philanthropic effort would be able to replace government-funded foreign aid.
'There is no foundation—or group of foundations—that can provide the funding, workforce capacity, expertise, or leadership that the United States has historically provided to combat and control deadly diseases and address hunger and poverty around the world,' Rob Nabors, the North America director for the Gates Foundation, told media outlets earlier this month.
The Novo Nordisk Foundation, one of the wealthiest charities in the world, likewise shied away from committing additional funding to foreign aid and will continue to focus on addressing non-communicable diseases like heart disease and diabetes.
'Of course, more people are contacting us…We don't have plans of stepping in, of filling gaps,' Flemming Konradsen, the Novo Nordisk Foundation's scientific director of global health, said in a February interview with Reuters.
These foundations are turning away from taking on the government's role in global health care aid because they aren't designed to do so, according to Jesse Lecy, associate professor of data science and nonprofit studies at Arizona State University.
'The capital needed to sustain an initiative dwarfs the levels of capital needed for pilot programs that can establish the efficacy of new approaches,' he told Fortune in an email. 'Scaling viable solutions requires partnerships.'
Philanthropic efforts are most effective when they invest in early research or pilot initiatives that are more risky, but less expensive. Then, nonprofits can build out and sustain successful projects in the long term, Lecy argued. Scaling nonprofits' projects is something far more expensive than what foundations have resources for.
'What people misunderstand about foundations is that they are the venture capital arm of philanthropy, not the long-term capital that sustains programming,' he said.
This story was originally featured on Fortune.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Eli Lilly raising GLP-1 prices abroad raises more questions about US pricing: BofA analyst
Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing in peer developed nations. The effort, known as Most Favored Nations pricing, has been a goal of Trump's since his first term. He has doubled down on the efforts this year, giving pharma companies 60 days to implement changes in pricing in what he deems "freeloading" nations. The US drug economy differs from European and other developed nations, which rely on the government to negotiate prices with drugmakers, resulting in lower prices globally. "While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the US that have contributed to high drug prices. The US system is complex and opaque," Lilly said in a statement Thursday. The stock was up 1% in trading Friday. Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would almost double its price. In a note to clients Friday, Bank of America Securities research analyst Tim Anderson questioned who would actually be impacted by the raised prices. "LLY has announced it will raise GLP-1 pricing in the UK by a healthy margin (a doubling of price, but it's unclear to whom this higher price realistically applies). It expects to do something similar in other European countries (but worth appreciating: in most European markets, there aren't price agreements in place between GLP-1 manufacturers and governments, meaning these are out-of-pocket spending markets)," Anderson wrote. Ultimately, whether or not the move results in lower US prices remains a question, though Anderson believes it likely will not. "Does this mean it will actually cut the price on the GLP-1s in the US (and on other medicines)? To us, the answer is quite likely no, or at least, not in a way that creates P&L [profit and loss planning ] risk," he wrote. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Times
7 hours ago
- New York Times
MAHA Draft Report Brings Relief to Some, Chagrin to Others
Some vocal allies of Health Secretary Robert F. Kennedy Jr. expressed dismay and alarm on Friday at what they saw as concessions to the powerful agriculture industry contained in the draft of an upcoming White House report on children's health. The draft, details of which The New York Times published on Thursday, offered proposals on food and pesticides that fell short of what many in Mr. Kennedy's Make America Healthy Again movement had hoped for. The disclosures reopened a bitter divide among supporters of President Trump over the clearest path to improving Americans' health. In one camp are MAHA followers, who, like the health secretary, have warned that chemicals are poisoning Americans, and they are demanding swift action to clean up the food supply. In another are influential agriculture, food and drug interests that have traditionally backed Republicans and see the specter of a crackdown on the food supply as a threat to their industries, as well as to product prices and jobs. Somewhere in the middle are more moderate allies of Mr. Kennedy, including MAHA supporters who say they understood that their revolution could not happen overnight. The draft report, a strategy document by a presidential commission established to improve children's health, is not final and will most likely change before its release in the coming weeks. Want all of The Times? Subscribe.
Time Business News
9 hours ago
- Time Business News
Debbie Wasserman Schultz on the Legislative Frontlines
Debbie Wasserman Schultz has built a reputation in Congress as a determined advocate for civil rights, healthcare reform, and public safety. Representing Florida in the U.S. House of Representatives since 2005, she has consistently championed legislation that addresses the needs of vulnerable communities while working to strengthen the nation's democratic values. Throughout her career, Debbie Wasserman Schultz has been a strong defender of civil rights. She has taken bold positions on issues ranging from voting rights to LGBTQ equality. As a member of Congress, she has supported legislation aimed at expanding voter access, opposing discriminatory practices, and ensuring that every citizen has an equal voice in the democratic process. Her advocacy extends to protecting religious and ethnic minorities. Most recently, she has been at the forefront of efforts to create a national strategy to combat antisemitism, working across party lines to address the rise in hate crimes and extremist rhetoric. She views these initiatives not only as a matter of protecting one community, but as a fundamental defense of American democracy. For Debbie Wasserman Schultz, healthcare reform has always been more than a talking point. A breast cancer survivor herself, she has been a leading voice for policies that expand access to preventive care and early detection services. Her leadership on the EARLY Act has helped fund breast cancer education programs for young women, potentially saving thousands of lives through increased awareness and timely screenings. She has also recently introduced the Reducing Hereditary Cancer Act, a bipartisan bill designed to make genetic cancer testing more accessible to Americans who are at risk. By removing financial and coverage barriers, she hopes to create a healthcare system that focuses on prevention and equity, ensuring no patient is denied care because of cost or insurance limitations. In addition to her work on civil rights and healthcare, Debbie Wasserman Schultz has been an advocate for public safety measures that protect communities while respecting individual rights. She has supported common-sense gun safety reforms, investments in law enforcement training, and improved coordination among public safety agencies. Her legislative work also extends to protecting children and families. She has championed laws like the Virginia Graeme Baker Pool and Spa Safety Act, which addresses child drownings by requiring safety standards for public pools and spas. These efforts reflect her broader commitment to legislation that has a tangible impact on everyday lives. While Congress is often marked by partisan gridlock, Debbie Wasserman Schultz has shown an ability to collaborate with colleagues from both sides of the aisle. Her bipartisan efforts on anti-hate initiatives, healthcare reform, and safety legislation demonstrate her belief that meaningful change requires cooperation and dialogue, even among political opponents. This approach has allowed her to move forward on initiatives that might otherwise stall in a divided political climate. By focusing on shared values such as safety, health, and equality, she has been able to advance legislation that benefits a broad range of Americans. As she continues her work in Congress, Debbie Wasserman Schultz remains committed to her core mission: defending civil rights, improving healthcare access, and safeguarding communities. She has made it clear that she sees these priorities as interconnected, with each influencing the strength and resilience of the nation as a whole. Her ongoing legislative efforts, from combating hate crimes to expanding medical testing access, are grounded in a belief that the government should be both responsive and proactive in addressing the needs of its people. This vision, combined with her experience and willingness to work across political divides, positions her as a significant force in shaping policy on some of the most pressing issues facing the country today. For constituents in Florida and for Americans across the nation, Debbie Wasserman Schultz continues to serve as a steadfast advocate, ensuring that civil rights, healthcare, and public safety remain at the top of the congressional agenda. TIME BUSINESS NEWS
